Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Fosun Partners In-Vitro Lung Cancer Diagnostic with VolitionRx

publication date: Jul 19, 2019

Shanghai Fosun Long March Medical Science struck a deal to bring the Nu.Q(TM) diagnostic platform developed by Belgium's VolitionRx to China. The two companies have already started a China clinical trial of a lung cancer diagnostic as the first application. Fosun Long March is the investment platform of the in-vitro diagnostics division of Fosun Pharma. In a China trial expected to be completed this year, Fosun Long March is collecting and testing blood samples using Volition's Nu.Q assays. More details....

Stock Symbols: (NYSE AM: VNRX) (SHA: 600196; HK: 2196)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital